Figure 2

Effect of in vitro MB-aPDT treatment in SARS-CoV-2 patient-derived samples. (A) RT-qPCR analysis of 6 samples treated with MB-aPDT (10 min incubation at 10 μM and 30 J cm⁻²), together with control untreated and light-only or MB-only controls. *Samples with undetectable level of SARS-CoV-2. (B) Representative cytopathic effect (CPE) slides for aPDT-treated and control untreated samples #1 and #4. No viral load can be seen post-aPDT. In P0d4 and P1d4, P represents the cell passage number and d the day of analysis. Significant reductions were observed between the aPDT and control groups in both viral RNA copies/μl and infectivity (P < 0.05).